Pfizer Inc.
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer

Abstract:

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective 4-1 BB agonist, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.